Filters
Results 1 - 10 of 194
Results 1 - 10 of 194.
Search took: 0.018 seconds
Sort by: date | relevance |
Monnier, Alain, E-mail: amonnier@chbm.fr2010
AbstractAbstract
[en] The use of third-generation aromatase inhibitors (AIs), such as anastrozole and letrozole, as initial adjuvant hormonal therapy in postmenopausal women (PMW) with hormone receptor-positive (HR+) breast cancer offers a significant benefit over tamoxifen for reducing recurrence risk. Clinical studies, including the Arimidex Tamoxifen Alone or in Combination (ATAC) and the Breast International Group (BIG) 1–98 trials, have proven that both anastrozole and letrozole are, respectively, superior to tamoxifen in improving disease-free survival. Although differing in design, objectives, and follow-up time, these trials offer some insight into the comparative clinical efficacy of these two nonsteroidal AIs. In particular, results from BIG 1–98 show that letrozole significantly reduces early distant metastatic (DM) events, which constitute the majority of early recurrence events. Subsequently, there is a beneficial overall survival effect emerging in the trial, whereas survival is unchanged with anastrozole after 100 months of follow-up in ATAC. Significant differences in the potency of these two drugs, vis-à-vis their degree of aromatase inhibition, have been observed in comparative trials and show that letrozole causes a more complete suppression of estrogen levels than does anastrozole. Whether this difference in potency is relevant to reductions in DM events during adjuvant therapy remains unclear. The Femara Anastrozole Clinical Evaluation trial is addressing this issue in a more unequivocal manner by comparing initial adjuvant treatment with anastrozole or letrozole in a population of breast cancer patients at high risk of recurrence: PMW with HR+ disease and axillary lymph node involvement
Primary Subject
Source
Available from http://dx.doi.org/10.2147/CMR.S13511; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004571; PMCID: PMC3004571; PMID: 21188118; PUBLISHER-ID: cmr-2-267; OAI: oai:pubmedcentral.nih.gov:3004571; Copyright (c) 2010 Monnier, publisher and licensee Dove Medical Press Ltd.; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 2; p. 267-276

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Reguart, Noemí; Cardona, Andrés Felipe; Rosell, Rafael, E-mail: nreguart@clinic.ub.es2010
AbstractAbstract
[en] Erlotinib hydrochloride (Tarceva"®) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as “targeted therapies” designed to act upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its approval in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with a view to improving patients’ outcomes and prevent symptoms, the scientific community has evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, in first-line setting for a selected population based on biological markers of response such as mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity profile of erlotinib make it a reasonable candidate for testing in this context. This report provides a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as looking at candidate biomarkers of response to these new targeted-agents
Primary Subject
Source
Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004579; PMCID: PMC3004579; PMID: 21188105; PUBLISHER-ID: cmr-2-143; OAI: oai:pubmedcentral.nih.gov:3004579; Copyright (c) 2010 Reguart et al, publisher and licensee Dove Medical Press Ltd.; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 2; p. 143-156

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Anandappa, G; Hollingdale, AE; Eisen, TG, E-mail: tim.eisen@medschl.cam.ac.uk2010
AbstractAbstract
[en] With the increasing understanding of the biology of the disease and the development of targeted therapy, there has been a paradigm shift in the treatment of clear cell metastatic renal cell carcinoma (mRCC). Traditionally patients with metastatic RCC have been treated with immunotherapy which has limited efficacy. The multikinase inhibitors sunitinib, sorafenib and pazopanib, the VEGF antibody bevacizumab in combination with interferon and the mTOR inhibitor temsirolimus have all been shown to prolong progression-free survival in phase III studies. Here we review another mTOR inhibitor, everolimus (Afinitor"®; Novartis, USA) which was approved in March 2009 by the US FDA for treatment of targeted-therapy refractory metastatic renal cell cancer. The phase III study of everolimus (the RECORD study) was terminated early after a significant difference in efficacy was noted in the treatment arm with everolimus (progression-free survival of 4.0 months in patients on the treatment arm vs 1.9 months in the placebo arm). The most common adverse events were stomatitis, pneumonitis, fatigue and infections. We review Phase I–III data with a particular emphasis on safety data and patient focused outcomes
Primary Subject
Source
Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004583; PMCID: PMC3004583; PMID: 21188097; PUBLISHER-ID: cmr-2-061; OAI: oai:pubmedcentral.nih.gov:3004583; Copyright (c) 2010 Anandappa et al, publisher and licensee Dove Medical Press Ltd.; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 2; p. 61-70

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Human epidermal growth factor receptor 2 (HER2)/neu, topoisomerase II alpha (TOP2A), and polysomy 17 may predict tumor responsiveness to doxorubicin (DOX) therapy. We identified neoadjuvant DOX/cyclophosphamide treated breast cancer patients in our registry from 1997 to 2008 with sufficient tissue for testing (n = 34). Fluorescence in situ hybridization (FISH) testing was done on deparaffinized tissue sections pretreated using vendor’s standard protocol modification, and incubated with US Food and Drug Administration approved Abbott Diagnostics Vysis PathVysion™ probe set, including Spectrum-Green-conjugated probe to α-satellite DNA located at the centromere of chromosome 17 (17p11.1–q11.1) and a Spectrum-Orange-conjugated probe to the TOP2A gene. Morphometric analysis was performed using a MetaSystems image analysis system. Manual counting was performed on all samples in which autofluorescence and/or artifact prevented the counting of sufficient numbers of cells. A ratio >2.0 was considered positive for TOP2A amplification. Polysomy 17 (PS17) presence was defined as signals of ≥2.5. Outcomes were pathological complete response (pCR), partial response (PR), and nonresponse (NR). Of 34 patients tested, one was TOP2A amplified (hormone receptor negative/HER2 negative, partial responder). The subset of TOP2A nonamplified, HER2 negative, and PS17 absent (n = 23) patients had treatment response: pCR = 2 (9%), PR = 14 (61%), and NR = 7 (30%). Including the two PS17 present and HER2-positive patients (n = 33), 76% of TOP2A nonamplified patients had pCR or PR. We observed substantial treatment response in patients lacking three postulated predictors that would be difficult to attribute to cyclophosphamide alone. Patients who are HER2 negative and lack TOP2A amplification and PS17 should not be excluded from receiving DOX-containing regimens
Primary Subject
Secondary Subject
Source
Available from http://dx.doi.org/10.2147/CMR.S12849; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004590; PMCID: PMC3004590; PMID: 21188112; PUBLISHER-ID: cmr-2-213; OAI: oai:pubmedcentral.nih.gov:3004590; Copyright (c) 2010 Kaplan et al, publisher and licensee Dove Medical Press Ltd.; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 2; p. 213-218

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Cobham, Marta Vallee; Donovan, Diana, E-mail: mac2034@med.cornell.edu2009
AbstractAbstract
[en] Ixabepilone (Ixempra"®; Bristol-Myers Squibb) is a novel microtubule stabilizing agent recently approved for the treatment of metastatic breast cancer (MBC). This article focuses on considerations for ixabepilone administration and adverse event (AE) management, drawing from the biomedical literature indexed in PubMed, published abstracts from the American Society of Clinical Oncology annual meetings, and the manufacturer’s prescribing information for ixabepilone. Administered as monotherapy or in combination with capecitabine in clinical studies, ixabepilone demonstrated positive clinical response rates, prolonged progression-free survival, and a favorable safety profile in patients with MBC. Treatment-related AEs were predictable and manageable with dose modification, treatment interruption, and active management. As ixabepilone undergoes development in earlier lines of breast cancer therapy and in other solid tumors, oncology nurses will encounter more and more patients receiving ixabepilone therapy. If nurses are acquainted with the unique management strategies associated with ixabepilone treatment, as detailed herein, patients are more likely to receive the full benefit of therapy
Primary Subject
Source
Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004658; PMCID: PMC3004658; PMID: 21188125; PUBLISHER-ID: cmr-1-069; OAI: oai:pubmedcentral.nih.gov:3004658; Copyright (c) 2009 Cobham and Donovan, publisher and licensee Dove Medical Press Ltd.; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 1; p. 69-77

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Bonetta, Alberto; Di Pierro, Francesco, E-mail: f.dipierro@vellejaresearch.com2012
AbstractAbstract
[en] Cranberry (Vaccinium macrocarpon) proanthocyanidins can interfere with adhesion of bacteria to uroepithelial cells, potentially preventing lower urinary tract infections (LUTIs). Because LUTIs are a common side effect of external beam radiotherapy (EBRT) for prostate cancer, we evaluated the clinical efficacy of enteric-coated tablets containing highly standardized V. msacrocarpon (ecVM) in this condition. A total of 370 consecutive patients were entered into this study. All patients received intensity-modulated radiotherapy for prostate cancer; 184 patients were also treated with ecVM while 186 served as controls. Cranberry extract therapy started on the simulation day, at which time a bladder catheterization was performed. During EBRT (over 6–7 weeks), all patients underwent weekly examination for urinary tract symptoms, including regular urine cultures during the treatment period. Compliance was excellent, with no adverse effects or allergic reactions being observed, apart from gastric pain in two patients. In the cranberry cohort (n = 184), 16 LUTIs (8.7%) were observed, while in the control group (n = 186) 45 LUTIs (24.2%) were recorded. This difference was statistically significant. Furthermore, lower rates of nocturia, urgency, micturition frequency, and dysuria were observed in the group that received cranberry extract. Cranberry extracts have been reported to reduce the incidence of LUTIs significantly in women and children. Our data extend these results to patients with prostate cancer undergoing irradiation to the pelvis, who had a significant reduction in LUTIs compared with controls. These results were accompanied by a statistically significant reduction in urinary tract symptoms (dysuria, nocturia, urinary frequency, urgency), suggesting a generally protective effect of cranberry extract on the bladder mucosa
Primary Subject
Source
Available from http://dx.doi.org/10.2147/CMAR.S35342; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437800; PMCID: PMC3437800; PMID: 22977312; PUBLISHER-ID: cmar-4-281; OAI: oai:pubmedcentral.nih.gov:3437800; Copyright (c) 2012 Bonetta and Di Pierro, publisher and licensee Dove Medical Press Ltd.; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 4; p. 281-286

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] Radium-223 chloride ("2"2"3Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), "2"2"3Ra delivers a high quantity of energy per track length with short tissue penetration. This review describes the mechanism, radiobiology, and preclinical development of "2"2"3Ra and discusses the clinical data currently available regarding its safety and efficacy profile. Data from clinical trials including abstracts were collected and reviewed using the PubMed Database, as well as the American Society of Clinical Oncology abstract database. Current bone-targeted therapies fall into two main categories: antiresorptive agents (eg, zoledronic acid, denosumab), which have been shown to delay skeletal-related events, and radiopharmaceuticals (eg, samarium-153), which may have a role in pain palliation. Historically, neither antiresorptive agents nor radiopharmaceuticals have shown definitive evidence of improved overall survival or other antitumor effects in metastatic castrate-resistant prostate cancer (mCRPC). Radiopharmaceuticals are limited by myelosuppresion, thrombocytopenia, and renal excretion. In a recently reported randomized Phase III trial in men with symptomatic bone-metastatic CRPC who had received or were ineligible for docetaxel chemotherapy, "2"2"3Ra treatment resulted in improved overall survival and delayed skeletal-related events. Toxicity consisted of minor gastrointestinal side effects and mild neutropenia and thrombocytopenia that were rarely severe. Pending regulatory approval, "2"2"3Ra may represent a unique and distinct option for an important subgroup of patients with mCRPC; future trials should address its use in combination or in sequence with existing and novel agents
Primary Subject
Source
Available from http://dx.doi.org/10.2147/CMAR.S25537; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544343; PMCID: PMC3544343; PMID: 23326203; PUBLISHER-ID: cmar-5-001; OAI: oai:pubmedcentral.nih.gov:3544343; Copyright (c) 2013 Harrison et al, publisher and licensee Dove Medical Press Ltd; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 5; p. 1-14

Country of publication
ALKALINE EARTH ISOTOPES, BETA DECAY RADIOISOTOPES, BETA-MINUS DECAY RADIOISOTOPES, BODY, CHLORINE COMPOUNDS, DAYS LIVING RADIOISOTOPES, DIGESTIVE SYSTEM, DISEASES, DRUGS, EVEN-ODD NUCLEI, GASTROINTESTINAL TRACT, GLANDS, HALIDES, HALOGEN COMPOUNDS, INTERMEDIATE MASS NUCLEI, INTESTINES, ISOTOPES, LABELLED COMPOUNDS, MALE GENITALS, MATERIALS, MEDICINE, NUCLEAR MEDICINE, NUCLEI, ORGANS, RADIOACTIVE MATERIALS, RADIOISOTOPES, RADIOLOGY, RARE EARTH NUCLEI, SAMARIUM ISOTOPES, STRONTIUM ISOTOPES, TESTING, THERAPY
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] Medullary thyroid carcinoma (MTC) is a rare malignant tumor originating from thyroid parafollicular C cells. This tumor accounts for 3%–4% of thyroid gland neoplasias. MTC may occur sporadically or be inherited. Hereditary MTC appears as part of the multiple endocrine neoplasia syndrome type 2A or 2B, or familial medullary thyroid cancer. Germ-line mutations of the RET proto-oncogene cause hereditary forms of cancer, whereas somatic mutations can be present in sporadic forms of the disease. The RET gene encodes a receptor tyrosine kinase involved in the activation of intracellular signaling pathways leading to proliferation, growth, differentiation, migration, and survival. Nowadays, early diagnosis of MTC followed by total thyroidectomy offers the only possibility of cure. Based on the knowledge of the pathogenic mechanisms of MTC, new drugs have been developed in an attempt to control metastatic disease. Of these, small-molecule tyrosine kinase inhibitors represent one of the most promising agents for MTC treatment, and clinical trials have shown encouraging results. Hopefully, the cumulative knowledge about the targets of action of these drugs and about the tyrosine kinase inhibitor-associated side effects will help in choosing the best therapeutic approach to enhance their benefits
Primary Subject
Source
Available from http://dx.doi.org/10.2147/CMAR.S33105; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658436; PMCID: PMC3658436; PMID: 23696715; PUBLISHER-ID: cmar-5-057; OAI: oai:pubmedcentral.nih.gov:3658436; Copyright (c) 2013 Ferreira et al, publisher and licensee Dove Medical Press Ltd; This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 5; p. 57-66

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Dong, Yujuan; Yu, Jun; Ng, Simon SM, E-mail: simonng@surgery.cuhk.edu.hk2014
AbstractAbstract
[en] Colorectal cancer (CRC) is one of the most potentially curable cancers, yet it remains the fourth most common overall cause of cancer death worldwide. The identification of robust molecular prognostic biomarkers can refine the conventional tumor–node–metastasis staging system, avoid understaging of tumor, and help pinpoint patients with early-stage CRC who may benefit from aggressive treatments. Recently, epigenetic studies have provided new molecular evidence to better categorize the CRC subtypes and predict clinical outcomes. In this review, we summarize recent findings concerning the prognostic potential of microRNAs (miRNAs) in CRC. We first discuss the prognostic value of three tissue miRNAs (miR-21-5p, miR-29-3p, miR-148-3p) that have been examined in multiple studies. We also summarize the dysregulation of miRNA processing machinery DICER in CRC and its association with risk for mortality. We also reviewe the potential application of miRNA-associated single-nucleotide polymorphisms as prognostic biomarkers for CRC, especially the miRNA-associated polymorphism in the KRAS gene. Last but not least, we discuss the microsatellite instability-related miRNA candidates. Among all these candidates, miR-21-5p is the most promising prognostic marker, yet further prospective validation studies are required before it can go into clinical usage
Primary Subject
Source
Available from http://dx.doi.org/10.2147/CMAR.S35164; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206254; PMCID: PMC4206254; PMID: 25342918; PUBLISHER-ID: cmar-6-405; OAI: oai:pubmedcentral.nih.gov:4206254; Copyright (c) 2014 Dong et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License; The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 6; p. 405-422

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] Phyllodes tumors are rare fibroepithelial neoplasms that account for less than 1% of all breast tumors and are typically found in middle-aged women. Phyllodes tumors that present with hypoglycemia are even rarer. No one morphologic finding is reliable in predicting the clinical behavior of this tumor. Surgery has been the primary mode of treatment to date. However, the extent of resection and the role of adjuvant radiotherapy or chemotherapy are still controversial. Here, we present a challenging case of malignant phyllodes tumor of the breast associated with hypoglycemia, and review the literature regarding clinical findings, pathologic risk factors for recurrence, and treatment recommendations
Primary Subject
Source
Available from http://dx.doi.org/10.2147/CMAR.S71933; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266253; PMCID: PMC4266253; PMID: 25525388; PUBLISHER-ID: cmar-6-467; OAI: oai:pubmedcentral.nih.gov:4266253; Copyright (c) 2014 Pacioles et al, publisher and licensee Dove Medical Press Ltd; This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancer Management and Research; ISSN 1179-1322;
; v. 6; p. 467-473

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
1 | 2 | 3 | Next |